An Open, Single-center Clinical Study of Surufatinib Combined With Temozolomide and S-1 in the First-line Treatment of Advanced Neuroendocrine Tumors
Clinical trial NCT06038461 · RECRUITING
Trial details
- NCT number
- NCT06038461
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-09-15
- Primary completion
- 2027-09-15
- Enrollment
- 40
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.